Coral Labs board to consider Q4FY26 results on May 30
Coral Laboratories Limited has scheduled a board meeting for May 30, 2026, to consider the standalone audited financial results for the quarter and year ended March 31, 2026. The agenda includes the recommendation of a final dividend, if any, and the appointment of internal and cost auditors for FY27. The trading window is closed from April 1, 2026, until 48 hours after the results declaration.

*this image is generated using AI for illustrative purposes only.
Coral Laboratories Limited has scheduled a meeting of its Board of Directors for Saturday, May 30, 2026. The meeting will be held to consider and approve the standalone audited financial results for the quarter and financial year ended March 31, 2026. The board will also evaluate the recommendation of a final dividend on equity shares for the year ended March 31, 2026, if any.
Agenda for the Meeting
The board's agenda includes several key administrative and financial approvals. Alongside the financial results, the directors will consider the appointment of an Internal Auditor and a Cost Auditor for the upcoming financial year 2026-27. The meeting will also cover any other business with the permission of the chairman.
Trading Window Closure
In accordance with the Company's Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the equity shares of the company has been closed. This restriction commenced on Wednesday, April 1, 2026, and will remain closed until 48 hours after the declaration of the financial results.
The intimation was signed by Sushma Kadkade, Director & CFO, on May 20, 2026, in Mumbai.
Historical Stock Returns for Coral Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.68% | +3.73% | +11.18% | -3.12% | -38.27% | -11.59% |
How does Coral Laboratories' expected dividend payout for FY2026 compare to its historical dividend track record, and what does it signal about the company's financial health?
What impact could the audited financial results for FY2026 have on Coral Laboratories' stock price movement once the trading window reopens?
How might the appointment of new Internal and Cost Auditors for FY2026-27 influence Coral Laboratories' operational efficiency and cost management strategies going forward?


































